Association of Treatment With Metformin vs Sulfonylurea With Major Adverse Cardiovascular Events Among Patients With Diabetes and Reduced Kidney Function

Abstract

In 2012, there were approximately 30 million US adults diagnosed as having type 2 diabetes, of whom 20% also had impaired kidney function.¹ Metformin is the initial recommended diabetes treatment based on the beneficial results reported in 1998 from the UK Prospective Diabetes Study (UKPDS) 34.^2,3 The UKPDS demonstrated that metformin reduced the incidence of macrovascular complications compared with sulfonylureas or insulin independent of glycemic control.^2,4 Several large observational studies support the UKPDS findings.^4-7